These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 17652776)

  • 1. Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane.
    Beyer K
    Cell Biochem Biophys; 2007; 47(2):285-99. PubMed ID: 17652776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Α-synuclein misfolding and Parkinson's disease.
    Breydo L; Wu JW; Uversky VN
    Biochim Biophys Acta; 2012 Feb; 1822(2):261-85. PubMed ID: 22024360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Lipids Interacting with α-Synuclein in the Pathogenesis of Parkinson's Disease.
    Galvagnion C
    J Parkinsons Dis; 2017; 7(3):433-450. PubMed ID: 28671142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions of α-synuclein oligomers with lipid membranes.
    Musteikytė G; Jayaram AK; Xu CK; Vendruscolo M; Krainer G; Knowles TPJ
    Biochim Biophys Acta Biomembr; 2021 Apr; 1863(4):183536. PubMed ID: 33373595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical properties of lipids strongly affect the kinetics of the membrane-induced aggregation of α-synuclein.
    Galvagnion C; Brown JW; Ouberai MM; Flagmeier P; Vendruscolo M; Buell AK; Sparr E; Dobson CM
    Proc Natl Acad Sci U S A; 2016 Jun; 113(26):7065-70. PubMed ID: 27298346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adsorption of α-synuclein to supported lipid bilayers: positioning and role of electrostatics.
    Hellstrand E; Grey M; Ainalem ML; Ankner J; Forsyth VT; Fragneto G; Haertlein M; Dauvergne MT; Nilsson H; Brundin P; Linse S; Nylander T; Sparr E
    ACS Chem Neurosci; 2013 Oct; 4(10):1339-51. PubMed ID: 23823878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein.
    Uversky VN; Eliezer D
    Curr Protein Pept Sci; 2009 Oct; 10(5):483-99. PubMed ID: 19538146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting alpha-synuclein for the treatment of Parkinson's disease.
    Rohn TT
    CNS Neurol Disord Drug Targets; 2012 Mar; 11(2):174-9. PubMed ID: 22483285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain.
    Roberts RF; Wade-Martins R; Alegre-Abarrategui J
    Brain; 2015 Jun; 138(Pt 6):1642-57. PubMed ID: 25732184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease.
    van Rooijen BD; Claessens MM; Subramaniam V
    Curr Protein Pept Sci; 2010 Aug; 11(5):334-42. PubMed ID: 20423294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Membrane bound α-synuclein is fully embedded in the lipid bilayer while segments with higher flexibility remain.
    Wietek J; Haralampiev I; Amoussouvi A; Herrmann A; Stöckl M
    FEBS Lett; 2013 Aug; 587(16):2572-7. PubMed ID: 23831067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein/lipid coaggregates are formed during α-synuclein-induced disruption of lipid bilayers.
    van Maarschalkerweerd A; Vetri V; Langkilde AE; Foderà V; Vestergaard B
    Biomacromolecules; 2014 Oct; 15(10):3643-54. PubMed ID: 25210839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Order and disorder in the physiological membrane binding of α-synuclein.
    Fusco G; Sanz-Hernandez M; De Simone A
    Curr Opin Struct Biol; 2018 Feb; 48():49-57. PubMed ID: 29100107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-Synuclein and Lewy pathology in Parkinson's disease.
    Kalia LV; Kalia SK
    Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of alpha-synuclein neurodegeneration.
    Waxman EA; Giasson BI
    Biochim Biophys Acta; 2009 Jul; 1792(7):616-24. PubMed ID: 18955133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.
    Uversky VN
    J Neurochem; 2007 Oct; 103(1):17-37. PubMed ID: 17623039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of α-synuclein is regulated in a neuronal cell type-dependent manner.
    Taguchi K; Watanabe Y; Tsujimura A; Tanaka M
    Anat Sci Int; 2019 Jan; 94(1):11-22. PubMed ID: 30362073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.